Internal Medicine
Online ISSN : 1349-7235
Print ISSN : 0918-2918
ISSN-L : 0918-2918
62 巻, 11 号
選択された号の論文の25件中1~25を表示しています
ORIGINAL ARTICLES
  • Hiroshi Kitamura, Junichi Nakazawa, Fumio Nagashima, Masahiko Andou, J ...
    2023 年 62 巻 11 号 p. 1573-1580
    発行日: 2023/06/01
    公開日: 2023/06/01
    [早期公開] 公開日: 2022/10/12
    ジャーナル オープンアクセス
    電子付録

    Objective To evaluate the effect of a pretreatment geriatric assessment on the clinical outcomes in older patients with unresectable or recurrent pancreatic ductal adenocarcinoma (PDAC) scheduled to receive gemcitabine (GEM)/GEM+nab-paclitaxel (GnP).

    Patients Older patients with unresectable PDAC scheduled to receive GEM/GnP who visited Kyorin University Hospital and cooperating institutions were enrolled and followed from April 2015 to March 2020. The maximum observation period was two years. All patients underwent a cancer-specific geriatric assessment (CSGA) and optional geriatric assessment (GA) before treatment initiation and two months after the start of treatment. The patients' background characteristics, tumor progression, tumor site, and regimen (GEM/GnP) were examined in a Cox proportional hazards model. The relationship between the overall survival (OS) and GA score was also determined. Eligible patients (age ≥70 years old with histopathologically confirmed unresectable or recurrent PDAC) were scheduled to receive first-line chemotherapy.

    Results The performance status (PS) and activities of daily living (ADL)/instrumental ADL (IADL) scores at baseline correlated with the OS. Furthermore, even in cases with normal baseline values, lower Frontal Assessment Battery scores and higher Geriatric Depression Scale-Short Form scores after treatment initiation were significantly correlated with OS.

    Conclusion The baseline PS, ADL, and IADL may be prognostic factors in older PDAC patients. In addition, a normal frontal lobe function and depression scores prior to treatment initiation that rapidly worsened during treatment were independently associated with a reduced OS. Selecting appropriate interventions and improving the therapeutic environment may prolong the OS in such patients.

  • Yuki Kuroyanagi, Asami Takeda, Hiroshi Kinashi, Yoshiyuki Kuroyanagi, ...
    2023 年 62 巻 11 号 p. 1581-1589
    発行日: 2023/06/01
    公開日: 2023/06/01
    [早期公開] 公開日: 2022/10/26
    ジャーナル オープンアクセス
    電子付録

    Objective Asymptomatic renal immunoglobulin A (IgA) deposition occurs in healthy subjects, but its etiologic role in disease is unclear. Galactose-deficient IgA1 (Gd-IgA1) is involved in the pathogenesis of IgA nephropathy. We investigated Gd-IgA1 deposition in transplanted kidneys that were considered healthy showing subclinical latent IgA deposition one hour after transplantation.

    Methods A total of 723 transplanted kidney specimens biopsied 1 h after kidney transplantation from 2009 to 2016 at Nagoya Red Cross Hospital were examined. A total of 81 cases of IgA deposition were extracted, and 41 were ultimately studied. Double immunofluorescence staining for Gd-IgA1 and IgA was conducted to investigate the role of Gd-IgA1 in subclinical IgA deposition.

    Results Light microscopy findings for the 41 cases indicated only minor glomerular abnormalities. Immunofluorescence analyses revealed that all cases were positive for IgA. C3, IgG, and IgM positivity rates were 78.0%, 7.3%, and 60.9%, respectively. All 41 cases were positive for Gd-IgA1, which merged with IgA deposition in immunofluorescence double staining. IgA disappeared in 26 of 40 cases (65.0%) 1 year after kidney transplantation. In contrast, IgA redeposition was observed in three cases.

    Conclusion Gd-IgA1 was demonstrated in all transplanted kidneys, with latent IgA deposition noted in otherwise healthy kidneys. Deposition of Gd-IgA1 might indicate the initial stage of IgA nephropathy; however, additional factors, such as IgG deposition, are required for the ultimate development of IgA nephropathy.

  • Jimi Oh, Gyeongseok Yu, Seung Won Ra
    2023 年 62 巻 11 号 p. 1591-1598
    発行日: 2023/06/01
    公開日: 2023/06/01
    [早期公開] 公開日: 2022/10/26
    ジャーナル オープンアクセス
    電子付録

    Objective Pleural infection is a significant disease that continues to pose severe problems for respiratory physicians. However, prognostic factors of pleural infection remain poorly understood. The controlling nutritional status (CONUT) score represents the immune-nutrition status of patients with chronic infectious diseases. This study investigated its prognostic value in patients with pleural infections.

    Methods We retrospectively analyzed a collected database of 2,363 patients who underwent thoracentesis and pleural fluid analyses between January 2010 and December 2019. Of these, only 335 patients with complicated parapneumonic effusion and empyema defined as pleural infection were included. They were divided into two groups based on the dichotomized CONUT score (i.e. <6 for low scores and ≥6 for high scores). The primary outcome was all-cause mortality within 90 days from the time of pleural fluid collection.

    Results Overall mortality was 8.4% at 3 months (28 out of 335). The incidence of 90-day mortality was higher in patients with higher CONUT scores than in those with lower scores [25.3% (21/84) vs. 2.8% (7/251), p<0.001]. In addition, after adjusting for confounders, a high CONUT score was found to be an independent prognostic factor for 90-day mortality (hazard ratio, 9.30; 95% confidence interval, 3.96-21.87; p<0.001).

    Conclusion Our study indicated that a high CONUT score was associated with an increased risk of 90-day mortality in patients with pleural infection and can be considered for clinical evaluations in practice.

  • Masaaki Matsushima, Monami Tarisawa, Taichi Nomura, Yuki Oshima, Masan ...
    2023 年 62 巻 11 号 p. 1599-1602
    発行日: 2023/06/01
    公開日: 2023/06/01
    [早期公開] 公開日: 2022/10/19
    ジャーナル オープンアクセス

    Objective Hereditary ATTR (ATTRv) amyloidosis was once an incurable disease; however, in recent years, disease-modifying therapies, such as tafamidis and patisiran, have become available. We herein report the medical care situation in an ATTRv amyloidosis non-endemic area of Japan.

    Methods We confirmed the information in the medical records of our department and analyzed the data retrospectively.

    Patients Patients with ATTRv amyloidosis who were treated in our department between 2010 and 2021 were included.

    Results A total of 15 ATTRv amyloidosis cases (8 men and 7 women) were treated in our department during the study period; 9 patients had a family history, and the transthyretin V30M (p.V50M) gene mutation was present in 66% of cases. The average age of the onset was 57 years old, with 73% of the initial symptoms being dysesthesia and 13% being autonomic dysfunction. Ten patients were treated with tafamidis and nine with patisiran. Although it took a long time to start treatment among our experienced cases, there were some cases in which treatment could be introduced relatively early.

    Conclusion ATTRv amyloidosis is treatable and should be included in the differential diagnosis of neuropathy so that it can be diagnosed early and introduced into treatment. In the near future, the presymptomatic diagnosis of ATTRv amyloidosis and genetic counseling will become more important.

CASE REPORTS
PICTURES IN CLINICAL MEDICINE
LETTERS TO THE EDITOR
feedback
Top